RefloDx Wins Trans Atlantic Angel Grand Prize

July 10, 2025

RefloDx competed in a field of 81 companies worldwide and won the grand prize investment from the Trans Atlantic Angel Competition 7 on June 12. The diligence team scrutinized financial projections, commercialization, regulatory, and reimbursement strategies, as well as IP review, and conducted detailed interviews with advisors, clinicians, and the RefloDx management team, including Rudy Wilcox, CEO, and Greg Critchfield, MD, MS, executive chair.

BioUtah congratulates RefloDx, which also won their category in the 2025 Entrepreneur & Investor Summit pitch competition.